$43.99
+0.29
(+0.66%)▲
Bristol-Myers Squibb Co is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.
0.65%
Downside
Day's Volatility :1.33%
Upside
0.69%
0.6%
Downside
52 Weeks Volatility :34.0%
Upside
33.6%
Period | Bristol-myers Squibb Co. | |
---|---|---|
3 Months | -8.92% | |
6 Months | -17.22% | |
1 Year | -34.6% | |
3 Years | -31.67% |
Market Capitalization | 90.9B |
Book Value | $14.56 |
Dividend Share | 1.74 |
Dividend Yield | 5.37% |
Earnings Per Share (EPS) | -3.1 |
PEG Ratio | 2.24 |
Wall Street Target Price | 54.24 |
Profit Margin | -13.5% |
Operating Margin TTM | 12.76% |
Return On Assets TTM | 5.63% |
Return On Equity TTM | 26.53% |
Revenue TTM | 45.5B |
Revenue Per Share TTM | 22.21 |
Quarterly Revenue Growth YOY | 4.7% |
Gross Profit TTM | 36.4B |
EBITDA | 17.5B |
Diluted Eps TTM | -3.1 |
Quarterly Earnings Growth YOY | -0.09 |
EPS Estimate Current Year | 0.52 |
EPS Estimate Next Year | 6.96 |
EPS Estimate Current Quarter | -4.44 |
EPS Estimate Next Quarter | 1.75 |
What analysts predicted
Upside of 23.3%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 22.6B | ↑ 8.59% |
Net Income | 5.0B | ↑ 391.76% |
Net Profit Margin | 21.95% | ↑ 17.1% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 26.1B | ↑ 15.89% |
Net Income | 3.4B | ↓ 30.55% |
Net Profit Margin | 13.15% | ↓ 8.8% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 42.5B | ↑ 62.62% |
Net Income | -9.0B | ↓ 361.56% |
Net Profit Margin | -21.16% | ↓ 34.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 46.4B | ↑ 9.09% |
Net Income | 7.0B | ↓ 177.75% |
Net Profit Margin | 15.08% | ↑ 36.24% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 46.2B | ↓ 0.49% |
Net Income | 6.3B | ↓ 9.54% |
Net Profit Margin | 13.71% | ↓ 1.37% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 45.0B | ↓ 2.5% |
Net Income | 8.0B | ↑ 26.84% |
Net Profit Margin | 17.83% | ↑ 4.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.4B | ↑ 1.68% |
Net Income | 2.0B | ↑ 25.9% |
Net Profit Margin | 17.73% | ↑ 3.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.3B | ↓ 0.6% |
Net Income | 2.3B | ↑ 11.87% |
Net Profit Margin | 19.95% | ↑ 2.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.2B | ↓ 0.98% |
Net Income | 2.1B | ↓ 8.36% |
Net Profit Margin | 18.47% | ↓ 1.48% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.0B | ↓ 2.32% |
Net Income | 1.9B | ↓ 6.99% |
Net Profit Margin | 17.58% | ↓ 0.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.5B | ↑ 4.66% |
Net Income | 1.8B | ↓ 8.61% |
Net Profit Margin | 15.35% | ↓ 2.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 11.9B | ↑ 3.38% |
Net Income | -11.9B | ↓ 775.99% |
Net Profit Margin | -100.39% | ↓ 115.74% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 10.7B | ↓ 68.23% |
Total Liabilities | 7.3B | ↓ 66.14% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 129.9B | ↑ 1119.1% |
Total Liabilities | 78.2B | ↑ 964.72% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 118.5B | ↓ 8.82% |
Total Liabilities | 80.6B | ↑ 3.01% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 109.3B | ↓ 7.74% |
Total Liabilities | 73.3B | ↓ 9.05% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 96.8B | ↓ 11.43% |
Total Liabilities | 65.7B | ↓ 10.38% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 95.2B | ↓ 1.72% |
Total Liabilities | 65.7B | ↓ 0.04% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 96.8B | ↓ 1.4% |
Total Liabilities | 65.7B | ↑ 0.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 94.3B | ↓ 2.62% |
Total Liabilities | 62.4B | ↓ 5.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 93.5B | ↓ 0.84% |
Total Liabilities | 61.5B | ↓ 1.5% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 91.3B | ↓ 2.38% |
Total Liabilities | 62.2B | ↑ 1.21% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 95.2B | ↑ 4.27% |
Total Liabilities | 65.7B | ↑ 5.58% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 99.0B | ↑ 4.07% |
Total Liabilities | 82.5B | ↑ 25.59% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.9B | ↑ 12.61% |
Investing Cash Flow | -874.0M | ↑ 1224.24% |
Financing Cash Flow | -3.5B | ↓ 13.29% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.1B | ↑ 35.81% |
Investing Cash Flow | -9.8B | ↑ 1017.85% |
Financing Cash Flow | 7.6B | ↓ 315.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.1B | ↑ 74.19% |
Investing Cash Flow | -10.9B | ↑ 11.15% |
Financing Cash Flow | -1.2B | ↓ 115.1% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 16.2B | ↑ 15.34% |
Investing Cash Flow | -538.0M | ↓ 95.05% |
Financing Cash Flow | -16.2B | ↑ 1309.56% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.1B | ↓ 19.38% |
Investing Cash Flow | -1.1B | ↑ 97.4% |
Financing Cash Flow | -17.0B | ↑ 4.55% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.9B | ↑ 6.08% |
Investing Cash Flow | -2.3B | ↑ 116.1% |
Financing Cash Flow | -9.4B | ↓ 44.49% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↓ 10.33% |
Investing Cash Flow | 1.2B | ↓ 158.29% |
Financing Cash Flow | -3.2B | ↓ 28.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.0B | ↓ 10.16% |
Investing Cash Flow | -210.0M | ↓ 117.31% |
Financing Cash Flow | -3.1B | ↓ 6.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↓ 36.46% |
Investing Cash Flow | -329.0M | ↑ 56.67% |
Financing Cash Flow | -2.2B | ↓ 28.75% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.8B | ↑ 151.78% |
Investing Cash Flow | -410.0M | ↑ 24.62% |
Financing Cash Flow | -5.2B | ↑ 137.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.3B | ↓ 10.5% |
Investing Cash Flow | -1.3B | ↑ 228.29% |
Financing Cash Flow | 967.0M | ↓ 118.74% |
Sell
Neutral
Buy
Bristol-myers Squibb Co. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Vanguard Group Inc
BlackRock Inc
JPMorgan Chase & Co
State Street Corporation
Capital Research & Mgmt Co - Division 3
FMR Inc
In the quarter ending March,2024. Bristol-myers Squibb Co. has declared dividend of $0.6
Read MoreThe Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Organization | Bristol-myers Squibb Co. |
Employees | 34100 |
CEO | Dr. Christopher S. Boerner Ph.D. |
Industry | Health Technology |